Company research
IR-Med, Inc.
CIK 1839133Updated Sep 24, 2026
SecurityIRME · OTC · equity
IRME price & chart
Loading TradingView…
OTC:IRME on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.01, 3.02, 5.02, 9.01
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 251,000Source | 999,000Source | 3,294,000Source | 2,943,000Source |
| Property, Plant and Equipment, NetUSD | 35,000Source | 56,000Source | 71,000Source | 31,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 129,000Source | 767,000Source | 3,002,000Source | 2,815,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 76,000Source | 81,000Source | 55,000Source | 67,000Source |
| Assets, CurrentUSD | 205,000Source | 848,000Source | 3,057,000Source | 2,882,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 84,000Source | 155,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 545,000Source | 634,000Source | 702,000Source | 572,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 70,000Source | 69,000Source | 68,000Source | 64,000Source |
| Additional Paid in CapitalUSD | 16,374,000Source | 15,135,000Source | 12,454,000Source | 7,503,000Source |
| Retained Earnings (Accumulated Deficit)USD | -16,738,000Source | -14,839,000Source | -9,930,000Source | -5,196,000Source |
| Stockholders' Equity Attributable to ParentUSD | -294,000Source | 365,000Source | 2,592,000Source | 2,371,000Source |
| Liabilities and EquityUSD | 251,000Source | 999,000Source | 3,294,000Source | 2,943,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 545,000Source | 473,000Source | 662,000Source | — |
| Accounts Payable, CurrentUSD | 114,000Source | 64,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 188,000Source | 160,000Source | 132,000Source | 140,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 485,000Source | 1,682,000Source | 1,330,000Source | 1,339,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -6,000Source | -6,000Source | -12,000Source | 38,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -1,386,000Source | -3,232,000Source | -3,375,000Source | -2,482,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | -2,000Source | -59,000Source | -61,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 2,000Source | 50,000Source | 31,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 750,000Source | 1,000,000Source | 3,625,000Source | 3,491,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -638,000Source | -2,235,000Source | 187,000Source | 949,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 534,000Source | — | — |
| DepreciationUSD | 21,000Source | 17,000Source | 10,000Source | 5,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,000Source | — | — | — |
| General and Administrative ExpenseUSD | 1,011,000Source | 2,028,000Source | 2,118,000Source | 1,368,000Source |
| Net Income (Loss) Attributable to ParentUSD | -1,899,000Source | -4,909,000Source | -4,734,000Source | -3,716,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,899,000Source | -4,909,000Source | -4,734,000Source | -3,716,000Source |
| Nonoperating Income (Expense)USD | -6,000Source | 2,000Source | 28,000Source | -41,000Source |
| Other Nonoperating Income (Expense)USD | -1,000Source | -1,000Source | -1,000Source | -1,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -1,941,000Source | -4,911,000Source | -4,762,000Source | -3,675,000Source |
| Other Nonoperating Income (Expense)USD | -1,000Source | -1,000Source | -1,000Source | -1,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 1,899,000Source | 4,909,000Source | 4,734,000Source | -3,716,000Source |
| Net Income (Loss) Attributable to ParentUSD | -1,899,000Source | -4,909,000Source | -4,734,000Source | -3,716,000Source |
| Earnings Per Share, BasicUSD per share | -0.03Source | -0.07Source | -0.07Source | — |
| Earnings Per Share, DilutedUSD per share | -0.03Source | -0.07Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 69,404,351Source | 67,577,734Source | 63,110,764Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 70,474,262Source | 69,404,351Source | — | — |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,000Source | — | — | — |
| General and Administrative ExpenseUSD | 1,011,000Source | 2,028,000Source | 2,118,000Source | 1,368,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 282,000Source | 346,000Source | 283,000Source | — |
| Interest Income (Expense), NetUSD | -3,000Source | 20,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,899,000Source | -4,909,000Source | -4,734,000Source | -3,716,000Source |
| Nonoperating Income (Expense)USD | -6,000Source | 2,000Source | 28,000Source | -41,000Source |
| Research and Development ExpenseUSD | 710,000Source | 2,061,000Source | 1,885,000Source | 1,419,000Source |
Filing attachments
ex4-1.htm · 8-K · 2026-06-03
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗